Clinical Trial Detail

NCT ID NCT01392183
Title Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

clear cell renal cell carcinoma

Therapies

Diphenhydramine

Temsirolimus

Pazopanib

Age Groups: adult senior

No variant requirements are available.